Prednisolone
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1955
- First approval year
- 1955
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Prednisolone
- Molecular weight
- 360.45
- Structure (SMILES)
- C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO
- cortalone
- Cortalone
- dekotil
- Dekotil
- delta cortef
- Delta-cortef
- deltacortril
- Deltacortril
- deltalone
- Deltalone
- dilacort
- Dilacort
- equisolon
- Equisolon
- fernisolone p
- Fernisolone-p
- hydeltra
- Hydeltra
- meti derm
- Meti-derm
- pevanti
- Pevanti
- precortisyl
- Precortisyl
- precortisyl fte
And 11 more, listed on the interactive page.
- (+)-PREDNISOLONE
- aprednislon
- Aprednislon
- chloroptic p s o p component prednisolone
- CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
- codelcortone
- Codelcortone
- cortalone
- CORTALONE
- corticosteroids (Aprednislon)
- corticosteroids aprednislon
- dekotil
- DEKOTIL
- delta cortef
- DELTA-CORTEF
- deltacortril
- Deltacortril
- DELTACORTRIL
- deltahydrocortisone
- Deltahydrocortisone
- deltalone
- DELTALONE
- dilacort
- DILACORT
- equisolon
And 98 more, listed on the interactive page.
- CAS registry numbers
- 50-24-8
- ChEMBL ID
- CHEMBL131
- InChIKey
- OIGNJSKKLXVSLS-VWUMJDOOSA-N
- PubChem compound IDs
- 5755
- FDA ingredient codes (UNII)
- 9PHQ9Y1OLM
- A01AC04
- A01AC54
- A07EA01
- C05AA04
- D07AA03
- D07XA02
- H02AB06
- R01AD02
- R01AD52
- S01BA04
- S01CB02
- S02BA03
- S03BA02
Sources for recorded values
- 8638
- 34372
- Applicant
- SCHERING
- Approval date
- 22 May 1955
- Application number
- NDA010255
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- prednisolone
- Type
- Synthetic organic
- Drug name stem
- -olone; pred-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- topical
- Action
- Agonist
- Action type
- Agonist
- Target
- Mineralocorticoid receptor
- Gene symbol
- NR3C2
- Protein identifier
- P08235
- Median affinity
- 7.43
- Affinity units
- pKi
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Protein identifier
- P04150
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- Glucocorticoid receptor
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Median affinity
- 7.8
- Affinity units
- pIC50
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Neoplasms, Plasma Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000200
- Subject identifier
- D054219
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000209
- Subject identifier
- D015456
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Immunoblastic Lymphadenopathy
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000255
- Subject identifier
- D007119
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Cardiomyopathies
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000318
- Subject identifier
- D009202
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Crohn Disease
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Dermatomyositis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000398
- Subject identifier
- D003882
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Infertility
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000545
- Subject identifier
- D007246
- Condition
- Leukemia
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Psoriasis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Sjogren's Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000699
- Subject identifier
- D012859
- Condition
- Stroke
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000712
- Subject identifier
- D020521
And 135 more, listed on the interactive page.
- Condition identifier
- EFO_0000220
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000274
- Condition identifier
- EFO_0000318
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000384
- Condition identifier
- EFO_0000398
- Condition identifier
- EFO_0000400
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000545
- Condition identifier
- EFO_0000565
- Condition identifier
- EFO_0000574
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000673
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000676
- Condition identifier
- EFO_0000685
- Condition identifier
- EFO_0000712
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000717
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000729
- Condition identifier
- EFO_0000759
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001054
- Condition identifier
- EFO_0001060
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 3
And 382 more, listed on the interactive page.
- Event
- anti-cyclic citrullinated peptide antibody positive
- Reports
- 1,133
- Reporting signal score
- 2,445.74
- Event
- cytomegalovirus infection
- Reports
- 2,194
- Reporting signal score
- 3,156.18
- Event
- cytomegalovirus viraemia
- Reports
- 239
- Reporting signal score
- 495.104
- Event
- epstein-barr virus infection
- Reports
- 307
- Reporting signal score
- 577.737
- Event
- febrile neutropenia
- Reports
- 4,674
- Reporting signal score
- 4,151.62
- Event
- glossodynia
- Reports
- 2,021
- Reporting signal score
- 3,270.25
- Event
- hand deformity
- Reports
- 1,695
- Reporting signal score
- 3,114.77
- Event
- neutropenia
- Reports
- 5,374
- Reporting signal score
- 2,235.77
- Event
- nocardiosis
- Reports
- 260
- Reporting signal score
- 655.765
- Event
- pemphigus
- Reports
- 2,586
- Reporting signal score
- 5,583.56
- Event
- pneumocystis jirovecii pneumonia
- Reports
- 1,568
- Reporting signal score
- 2,631.45
- Event
- polyomavirus-associated nephropathy
- Reports
- 267
- Reporting signal score
- 655.776
- Event
- post transplant lymphoproliferative disorder
- Reports
- 305
- Reporting signal score
- 629.308
- Event
- rheumatoid arthritis
- Reports
- 4,237
- Reporting signal score
- 2,558.88
- Event
- systemic lupus erythematosus
- Reports
- 2,584
- Reporting signal score
- 3,499.4
- Event
- transplant rejection
- Reports
- 444
- Reporting signal score
- 828.067
- NCT00002531
- NCT00002532
- NCT00002700
- NCT00002757
- NCT00003437
- NCT00003728
- NCT00004034
- NCT00004218
- NCT00015873
- NCT00400946
- NCT00618501
- NCT01005758
- NCT00002576
- NCT00002987
- NCT00003421
- NCT00003423
- NCT00003815
- NCT00005867
- NCT00025064
- NCT00031902
- NCT00032149
- NCT00079105
- NCT00275106
- NCT00433459
- NCT00513955
And 262 more, listed on the interactive page.
- Dose
- Varies from 2.5 mL to 30 mL (5 to 60 mg prednisolone base) per day
- Route
- Oral
- How often
- As needed
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 3
- Polar surface area
- 94.83
- Calculated partition coefficient (ALogP)
- 1.56
- Calculated partition coefficient (XLogP)
- 1.6
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 26
- Molecular formula
- C21H28O5
- Monoisotopic mass
- 360.19367399
- Natural product
- Yes
- 0121-0885
- 0527-5406
- 23155-927
- 42658-160
- 59651-491
- 62135-250
- 62135-437
- 68999-250
- 70404-077
- 50090-7115
- 60722-5011
- Recorded assays
- 3,799
- Active assays
- 227
- Confirmatory
- Other
- Screening
- Summary
- Anti-Inflammatory Agents
- Glucocorticoids
- Antineoplastic Agents, Hormonal
These details could not be displayed.
Related records
Trials (701)
- "Randomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity Pneumonitis"
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients
- 4"S" - Seasonal Symptoms Suppression Study
- 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
- A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma
- A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus
- A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
- A Comparison of Two Different Single Doses of Prednisolone on Endodontic Inter-appointment Pain
- A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
- A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.
- A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients
- A Phase 1 Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers
- A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
- A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
Approved for (56)
- Allergic rhinitis
- Ankylosing spondylitis
- Aplastic anemia
- Asthma
- Atopic conjunctivitis
- Atopic eczema
- Chorioretinitis
- Choroiditis
- Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
- Contact dermatitis
- Crohn disease
- Dermatitis herpetiformis
- Dermatomyositis
- Eosinophilic pneumonia
- Epicondylitis
- Erythema multiforme
- Exfoliative dermatitis
- Eye disorder
- Frozen shoulder
- Gout
In development for (99)
- ACTH-dependent Cushing syndrome Phase 2
- Acute lymphoblastic leukemia Phase 3
- Adrenocortical insufficiency Phase 3
- Age-related macular degeneration Phase 1
- Alcoholic hepatitis Phase 3
- Alcoholic liver disease Phase 3
- Allergic bronchopulmonary aspergillosis Phase 3
- Allergic disease Phase 3
- Anaplastic large cell lymphoma Phase 2
- Angioimmunoblastic T-cell lymphoma Phase 2
- Anti-neutrophil antibody associated vasculitis Phase 3
- Autoimmune hemolytic anemia Phase 3
- Autoimmune thrombocytopenic purpura Phase 3
- Bell's palsy Phase 1
- Biliary atresia Phase 3
- Breast cancer Phase 2
- Cancer Phase 1
- Canker sore Phase 2
- Cardiomyopathy Phase 2
- Cataract Phase 3
Other linked conditions (7)
- Anosmia
- Bronchiolitis
- Carpal tunnel syndrome
- Diabetes mellitus
- Hypospadias
- Interstitial lung disease
- Pleural tuberculosis
Targets (1)
- NR3C1 Glucocorticoid receptor agonist